PDPhilippe Damier

Philippe Damier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Philippe Damier has a total of 399 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Navigating the Challenges of Shared Decision‐Making in Amyloid Immunotherapy for Alzheimer's Disease

    by Grâce François, Robin Michalon, Thomas Tannou, Philippe Damier, Sonia Desmoulin, Thibaud Lebouvier

    Background: Anti‐amyloid therapies (AATs), such as lecanemab and donanemab, represent a major therapeutic development for early Alzheimer's disease (AD). However, safety risks and uncertainties regarding long‐term effects make treatment decisions complex. These decisions arise when patients remain legally capable of providing informed consent but may experience cognitive vulnerabilities affecting their ability to engage in complex decisions. Shared decision‐making (SDM) is therefore particularly relevant, yet its implementation raises ethical and practical challenges. Methods: This position paper draws on a multidisciplinary reflection on decision‐making, informed consent, and cognitive vulnerability in early AD and AATs. The authors, with expertise in neurology, geriatrics, law, and history, examined challenges to patient participation and developed a relational framework integrating SDM and supported decision‐making. Results: Impairments in memory, insight, and executive function, together with cognitive biases, stigma, and the complexity of AAT‐related information, may compromise patient participation despite preserved legal capacity. Formal capacity assessments and improved information delivery may address some difficulties but are unlikely to provide comprehensive support. We propose a relational framework involving assessment of patients' cognitive vulnerabilities, values, preferences, and informational needs; tailored information; and involvement of a patient‐designated care partner to support information exchange, deliberation, and expression of preferences. Consent should be iterative, with safeguards to preserve autonomy and confidentiality, prevent coercion, and avoid excluding socially isolated individuals. Conclusion: Combining SDM with supported decision‐making may provide an ethical and practical framework for autonomous treatment decisions regarding AATs in early AD.

  • Building Scalable Recruitment Models for Precision Medicine in Parkinson's Disease: Insights from GBA1 Trials

    by Jean‐Christophe Corvol, Christelle Tesson, Sophie Liot, Stéphanie Carvalho, Giovanni Castelnovo, Philippe Damier, Luc Defebvre, Caroline Giordana, Jean‐Luc Houeto, Ana Marques, et al.

  • Open Access

    Selective nigrosome vulnerability in Parkinson’s disease revealed by histology-anchored ultra-high-field quantitative MRI

    by Ruiyi Li, Evgeniya Kirilina, Pierre-Louis Bazin, Kjersti Eline Stige, Runa G. Unsgård, Malte Brammerloh, Ingrid Gylterud Kvålsgard, Anne Louise Kristoffersen, Erik Magnus Berntsen, Pål Erik Goa, et al.

    Selective vulnerability is a hallmark of Parkinson’s disease (PD): post-mortem, dopamine-containing cell loss in the substantia nigra first and most severely affects calbindin-poor compartments termed nigrosomes. Testing this in vivo has been limited by circularity, as MRI studies have delineated nigrosomes from the same disease-related contrast they then measure. Here, we warp histology-derived, calbindin-validated probabilistic masks of nigrosomes 1-5 into a cohort-specific multimodal 7 Tesla quantitative MRI template, providing a degeneration-independent anatomical scaffold, in 28 patients with PD and 28 age- and sex-matched controls. In controls, nigrosomes differ from the surrounding nigral matrix in magnetic susceptibility and R1. PD shifts nigrosomal values upward relative to the matrix in susceptibility, R2*, and R1, concentrated in nigrosomes 1, 2, and 4, whereas whole-nigra analysis shows no group difference. Within the matrix, disease effects are largest caudally and emerge dorsally from the ventral tier, and susceptibility alterations in nigrosomes 1 and 4 track contralateral motor symptoms asymmetry. The multimodal pattern suggests that the detectable signal reflects predominantly secondary, iron-associated glial processes rather than neuronal loss itself. These findings recover the post-mortem spatial pattern of nigral vulnerability in vivo and establish a degeneration-independent framework for subregional nigral imaging in PD.

  • Open Access

    Distinct Brain Drivers and Shared Cerebello–Cortical Input in ADCY5 and SGCE Hyperkinetic Movements

    by Clément Tarrano, Cécile Galléa, Asya Ekmen, Cécile Delorme, Eavan M. McGovern, Quentin Salardaine, Lina Daghsen, Manon Gomes, Vanessa Brochard, Eoin Mulroy, et al.

    Background: Hyperkinetic movement disorders arise from dysfunction within cortico–basal ganglia–cerebellar loops. They frequently involve psychiatric and cognitive symptoms, reflecting impairment of both motor and non‐motor domains within these loops. ADCY5 (MxMD‐ ADCY5 ) and SGCE (MYC/DYT‐ SGCE ) related movement disorders are childhood‐onset monogenic hyperkinetic conditions, both characterized by myoclonus, dystonia, and frequent psychiatric manifestations. Previous evidence suggests predominant basal ganglia involvement in MxMD‐ ADCY5 and cerebellar involvement in MYC/DYT‐ SGCE . Objectives: The aim was to determine how basal ganglia and cerebellar dysfunction drives cortical dysregulation in hyperkinetic movement disorders. Methods: Resting‐state functional magnetic resonance imaging (fMRI) was used to examine effective connectivity in motor and non‐motor cortico–basal ganglia–cerebellar loops. Findings were validated using leave‐one‐out cross‐validation. Microstructural properties of regions within these loops were assessed with diffusion‐weighted imaging, using neurite orientation dispersion and density measures. Results: We enrolled 21 patients with MxMD‐ ADCY5 , 24 with MYC/DYT‐ SGCE , and matched healthy controls. Both patient groups exhibited elevated rates of psychiatric comorbidities. In MxMD‐ ADCY5 , abnormal basal ganglia connectivity influenced the cerebellum, which in turn modulated cortical activity across motor and non‐motor loops. Reduced neurite density was observed in the subthalamic nucleus, a relay between basal ganglia and cerebellum. In MYC/DYT‐ SGCE , the cerebellum showed predominant influence on cortical activity, with downstream modulation of basal ganglia activity, but no microstructural alterations were detected. Cross‐validation largely confirmed the connectivity patterns' reliability. Conclusion: Abnormal cortical modulation in both disorders converges on a shared cerebellar–cortical pathway, with basal ganglia influences in MxMD‐ ADCY5 transmitted via the cerebellum to the cortex, and cerebellar contributions in MYC/DYT‐ SGCE directly influencing the cortex. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

  • Open Access

    Simulated shared and supported decision making for amyloid immunotherapy in Alzheimer's disease: A bicentric study

    by E. Burry, F. Plumacker, N. Villain, S. Amaral, P. Damier, J. Delrieu, M.-A. Mackowiak, R. Michalon, S. Mohr, V. Planche, et al.


  • Open Access

    Psychiatric Disorders and Apathy in Mixed Movement Disorders Linked to ADCY5 ( MxMD ‐ ADCY5 )

    by Aurélie Méneret, Clément Tarrano, Asya Ekmen, Diane Doummar, Victoria Gonzalez, Christine Tranchant, Mathieu Anheim, Philippe Damier, Eoin Mulroy, Kailash P. Bhatia, et al.

    Background: Mixed movement disorders linked to ADCY5 (MxMD‐ ADCY5 ) represent a rare hyperkinetic movement disorder resulting from pathogenic variants in ADCY5 . Psychiatric symptoms are suspected to be part of the phenotype. Objective: The study aim was to assess psychiatric comorbidities in patients with MxMD‐ ADCY5 . Methods: Consecutive patients were assessed with the MINI International Neuropsychiatric Interview (MINI), the shortened Beck Depression Inventory (BDI‐13), the Hospital Anxiety and Depression Scale (HADS), and the Starkstein Apathy Scale (SAS). Results: Twenty‐seven patients and 20 controls were included. Psychiatric disorders were present in 67% of patients compared with 15% of controls ( P = 0.00043), mainly anxiety (33% vs. 0%, P = 0.00862) and depression (44% vs. 10%, P = 0.01068). Depression, anxiety, and apathy scores were higher in patients (BDI‐13: 3.67 vs. 1.05, P = 0.004; HA: 6.71 vs. 3.90, P = 0.006; AS: 11.67 vs. 6.85, P = 0.001). Conclusion: Depression, anxiety, and apathy are likely part of the phenotypic spectrum of MxMD‐ ADCY5 . © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


  • Open Access

    Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa‐Therapy in Parkinson's Disease: A Randomized, Placebo‐Controlled Study ( PREMANDYSK )

    by Olivier Rascol, Fabienne Ory‐Magne, Wassilios G. Meissner, David Maltête, Luc Defebvre, Jean‐Philippe Azulay, Stéphane Thobois, Jean‐Luc Houeto, Claire Thalamas, Agnès Sommet, et al.

    Objective: Investigate the efficacy of immediate‐release (IR) amantadine in reducing the risk of peak‐dose dyskinesia in early Parkinson's disease (PD) as add‐on to levodopa. Background: While the use of amantadine to manage dyskinesia in PD is well supported by controlled clinical trials, data on its efficacy in patients without motor complications remain limited. Methods: This 22‐month, multicenter, randomized, placebo‐controlled trial (NCT01538329) enrolled early PD patients on stable levodopa (≥150 mg/day for ≤1 year) without motor complications. The study included three double‐blind phases: an 18‐month treatment phase with adjunct amantadine‐IR (200 mg/day) or placebo (Period 1), a 3‐month delayed‐start phase where all participants received amantadine‐IR (Period 2), and a 1‐month washout with placebo (Period 3). The primary outcome was dyskinesia incidence at month 18; secondary outcomes included dyskinesia rates at the end of Periods 2 and 3 to assess potential long‐lasting mechanisms of the drug. Exploratory outcomes investigated the potential effects of amantadine‐IR on motor and non‐motor symptoms and quality of life. Results: A total of 207 patients were randomized to amantadine‐IR (N = 99) or placebo (N = 108). Significantly fewer patients in the amantadine‐IR group developed dyskinesia versus placebo during Period 1 (11% vs. 22%, P = 0.025), while the mean daily dose of levodopa (95% CI) increased by 70 (21–119) mg less ( P = 0.005). The proportion of patients with dyskinesia was less in the amantadine‐IR group versus placebo at the end of Periods 2 and 3, but the difference was not statistically significant (12% vs. 20%, P = 0.13 and 16% vs. 22%, P = 0.23, respectively). Mild but significant positive effects on freezing of gait, fatigue, and quality of life were observed during Period 1. The safety profile of amantadine‐IR was in line with previous reports. Conclusions: Adjunctive amantadine‐IR in early PD halved dyskinesia incidence over 18 months. Long‐lasting mechanisms could not be demonstrated and merit further investigation. Exploratory positive findings on the potential benefit of amantadine‐IR on symptoms like freezing of gait and fatigue also call for further investigation. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.


  • Open Access

    Prodromal Parkinson's disease

    by L. Grass, S. Grimaldi, P. Damier


  • Open Access

    ADCY5 ‐Mosaic Variants: A Diagnosis Not to Be Missed

    by Alice Innocenti, Emmanuel Roze, Florence Riant, Marie‐Céline François‐Heude, Bérénice Lecardonnel, Giacomo Garone, Maxime Colmard, Eline Chauvet‐Piat, Anne‐Cécile Chaux, Marie‐Aude Spitz, et al.

    Background: An increasing number of ADCY5 ‐mosaic patients, seemingly with a milder phenotype, are being identified. However, an in‐depth assessment of their clinical characteristics is lacking. Cases: We collected and analyzed data from 12 consecutive ADCY5 ‐mosaic patients diagnosed at our center and 7 cases from the literature; 63% of the patients presented with a baseline hyperkinetic motor disorder with paroxysmal motor exacerbations; 30% had isolated paroxysmal dyskinesias (PxD). Caffeine treatment was highly effective. Developmental delay was observed in 5 patients and especially in those with persistent motor symptoms. PxD were the initial motor symptom in 70% of cases. Conclusions: ADCY5 ‐mosaic carriers may have the same phenotypic spectrum as non‐mosaic carriers but with a milder clinical presentation. Isolated PxD with onset in infancy are a red flag for ADCY5 ‐mosaic variants. Particular attention should be paid when genetic analysis of patients with this phenotype is conducted as mosaicism can be easily missed.


  • Top Cited Papers

    Trial of Lixisenatide in Early Parkinson’s Disease

    by Wassilios G. Meissner, Philippe Remy, Caroline Giordana, David Maltête, Pascal Derkinderen, Jean-Luc Houéto, Mathieu Anheim, Isabelle Benatru, Thomas Boraud, Christine Brefel-Courbon, et al.

    Lixisenatide, a glucagon-like peptide-1 receptor agonist used for the treatment of diabetes, has shown neuroprotective properties in a mouse model of Parkinson's disease. In this phase 2, double-blind, randomized, placebo-controlled trial, we assessed the effect of lixisenatide on the progression of motor disability in persons with Parkinson's disease. Participants in whom Parkinson's disease was diagnosed less than 3 years earlier, who were receiving a stable dose of medications to treat symptoms, and who did not have motor complications were randomly assigned in a 1:1 ratio to daily subcutaneous lixisenatide or placebo for 12 months, followed by a 2-month washout period. The primary end point was the change from baseline in scores on the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III (range, 0 to 132, with higher scores indicating greater motor disability), which was assessed in patients in the on-medication state at 12 months. Secondary end points included other MDS-UPDRS subscores at 6, 12, and 14 months and doses of levodopa equivalent. A total of 156 persons were enrolled, with 78 assigned to each group. MDS-UPDRS part III scores at baseline were approximately 15 in both groups. At 12 months, scores on the MDS-UPDRS part III had changed by -0.04 points (indicating improvement) in the lixisenatide group and 3.04 points (indicating worsening disability) in the placebo group (difference, 3.08; 95% confidence interval, 0.86 to 5.30; P = 0.007). At 14 months, after a 2-month washout period, the mean MDS-UPDRS motor scores in the off-medication state were 17.7 (95% CI, 15.7 to 19.7) with lixisenatide and 20.6 (95% CI, 18.5 to 22.8) with placebo. Other results relative to the secondary end points did not differ substantially between the groups. Nausea occurred in 46% of participants receiving lixisenatide, and vomiting occurred in 13%. In participants with early Parkinson's disease, lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months in a phase 2 trial but was associated with gastrointestinal side effects. Longer and larger trials are needed to determine the effects and safety of lixisenatide in persons with Parkinson's disease. (Funded by the French Ministry of Health and others; LIXIPARK ClinicalTrials.gov number, NCT03439943.).